 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 May 1994 | Volume 120 Issue 10 | Pages 834-844
Objective: To compare piperacillin and tobramycin with ceftazidime alone for the empiric treatment of fever in the neutropenic patient without evidence of skin infections or anaerobic infections.
Design: A multicenter, randomized, controlled trial.
Patients: 876 febrile, neutropenic episodes in 696 patients (83% acute leukemia or bone marrow transplantation); 92 episodes were excluded from analysis because of protocol violation.
Interventions: Patients received either intravenous ceftazidime (2 g every 8 h) or piperacillin (12 to 18 g/d in 4 to 6 divided doses plus tobramycin [1.7 to 2.0 mg/kg body weight every 8 h]. Treatment could be modified at any time at the discretion of the investigator.
Measurements: Percentage of satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events.
Results: As a single agent, ceftazidime was as effective as the combination of piperacillin and tobramycin (62.7% satisfactory responses compared with 61.1%; odds ratio, 1.07; 95% CI, 0.79 to 1.44; P > 0.2). Equivalent responses were also obtained in episodes of profound neutropenia (odds ratio, 0.76; CI, 0.43 to 1.33; P > 0.2). Infectious mortality was 6% for ceftazidime and 8% for the combination therapy. Eradication of the infecting organisms was achieved in 79% of bacteremic episodes treated with ceftazidime compared with 68% of the episodes treated with the combination therapy (odds ratio, 1.76; CI, 0.92 to 3.38; P = 0.08), and rates for gram-negative rod bacteremia were also similar (95% compared with 77%; odds ratio, 5.25; CI, 1.0 to 27.5; P = 0.03). Superinfections developed in 38 episodes in each group. An adverse event occurred in 8% of episodes treated with ceftazidime compared with 20% of episodes treated with combination therapy (P < 0.001).
Conclusion: Ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile, neutropenic patients, even those with profound and prolonged granulocytopenia.
Author and Article Information
For participating investigators and institutions, committee members, and current author addresses, see Appendix 1, Appendix 2, and end of text.
ARTICLE
Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial
For The Intercontinental Antimicrobial Study Group.
Requests for Reprints: Ben E. De Pauw, MD, PhD, Division of Hematology, University Hospital St. Radboud, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands.
Grant Support: Glaxo Group Research, Ltd., Greenford, Middlesex, United Kingdom, and its local subsidiaries financed the collection of data or supplied the study drugs free of charge.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Pizzo Where do we go from here? J. Antimicrob. Chemother., May 1, 2009; 63(suppl_1): i16 - i17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Williams Why monotherapy? J. Antimicrob. Chemother., May 1, 2009; 63(suppl_1): i18 - i20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. A. Blijlevens, R. M. Logan, and M. G. Netea Mucositis: from febrile neutropenia to febrile mucositis J. Antimicrob. Chemother., May 1, 2009; 63(suppl_1): i36 - i40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sung, L. L. Dupuis, B. Bliss, A. Taddio, M. Abdolell, U. Allen, M. Rolland, A. Tong, T. Taylor, and J. Doyle Randomized Controlled Trial of Once- Versus Thrice-Daily Tobramycin in Febrile Neutropenic Children Undergoing Stem Cell Transplantation J Natl Cancer Inst, December 17, 2003; 95(24): 1869 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Feld, B. DePauw, S. Berman, A. Keating, and W. Ho Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial J. Clin. Oncol., November 1, 2000; 18(21): 3690 - 3698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Chatzinikolaou, D. Abi-Said, G. P. Bodey, K. V. I. Rolston, J. J. Tarrand, and G. Samonis Recent Experience With Pseudomonas aeruginosa Bacteremia in Patients With Cancer: Retrospective Analysis of 245 Episodes Arch Intern Med, February 28, 2000; 160(4): 501 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Pizzo Fever in Immunocompromised Patients N. Engl. J. Med., September 16, 1999; 341(12): 893 - 900. [Full Text] [PDF]
|
|
|
|
|
|
G. Hoffken, R. Pasold, K. H. Pfluger, J. Finke, A. A. Fauser, H. Szelenyi, and J. Wagner An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients J. Antimicrob. Chemother., September 1, 1999; 44(3): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jaccard, N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, et al. Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2966 - 2972. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. F. Inciardi Empiric Therapy for Febrile Neutropenia Ann Intern Med, October 15, 1994; 121(8): 623 - 624. [Full Text]
|
|
|
|
|
|
B. E. DePauw and J. P. Donnelly Empiric Therapy for Febrile Neutropenia Ann Intern Med, October 15, 1994; 121(8): 623 - 624. [Full Text]
|
|
|
|
 |
|
 CEFTAZIDIME MONOTHERAPY FOR FEVER AND NEUTROPENIA Journal Watch (General), May 31, 1994; 1994(531): 4 - 4. [Full Text]
|
|
